Browsing Tag
European Commission
228 posts
Neuren Pharmaceuticals (ASX: NEU) lifts 2026 royalty outlook after record DAYBUE quarter
Record DAYBUE sales and rapid adoption of its STIX formulation have strengthened Neuren Pharmaceuticals’ royalty outlook, while Europe and Japan offer the next major tests of the franchise’s global potential.
The EU has started policing AI, and non-European companies are not outside its reach
EU AI Act enforcement begins with chatbot and deepfake disclosure rules, while delayed high-risk deadlines leave businesses facing a divided compliance map.
Brussels clears PSPIB and JERA Nex bp joint control of Taiwan’s Formosa 2
The EU cleared PSPIB and JERA Nex bp's joint control of Taiwan's 376MW Formosa 2 wind farm on 3 August, a capital-recycling signal one day before BP's Q2 results.
Saipem, Subsea7 clear US antitrust hurdle as Saipem7 merger heads for H2 2026 close
Saipem cleared US antitrust for the €21bn-revenue Saipem7 merger with Subsea7, but a Brussels Phase II probe and an Australian in-depth review remain.
NatWest Markets N.V. H1 2026: Balance sheet expands 43% as profit slips to €48m
NatWest Markets N.V. lifted total assets 43% to €40.6bn in H1 2026, yet profit slid to €48m as CET1 dropped to 17.7% and Argentina damages hit USD 1.1bn.
Spain deploys military to Ceuta after mass border crossings leave at least nine dead
Thousands entered Ceuta as Spain deployed troops and Morocco tightened controls. Nine deaths expose the human cost as Europe’s border crisis deepens again.
Behind RWE’s guidance upgrade: How much is one-off and how much is real?
RWE raised its 2026 and 2027 profit guidance, though a €332m Eemshaven payment and Amprion consolidation drove much of the H1 boost, not underlying growth.
Susvimo EU recommendation gives Roche a new weapon in the battle for longer-lasting eye treatments
Roche moves Susvimo toward EU approval as its refillable eye implant targets injection burden and strengthens a CHF 2.1 billion retinal franchise.
Neuraxpharm Group’s leriglitazone bet advances as European regulators back a narrow pediatric label
Minoryx Therapeutics revives its €258 million Neuraxpharm deal as leriglitazone moves closer to a narrow European rare-disease launch.
China targets 14 European entities as Russia sanctions trigger new EU trade confrontation
EU sanctions on Chinese suppliers have triggered immediate retaliation. European defence firms now face a new test of their dependence on Chinese inputs.